newsfilter
← Latest News
GlobeNewswire·

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

VTVT
  • vTv Therapeutics Inc. granted 4,000 stock options to a non-executive employee as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).
  • The stock options have an exercise price of $39.54 per share, matching the closing price on April 6, 2026.
  • Each option vests over a 4-year period with 25% vesting on the first-year anniversary & the remainder vesting quarterly over the subsequent 36 months.
  • The options have a 10-year term & are subject to the 2026 Inducement Plan & stock option agreement terms.
  • vTv Therapeutics is developing cadisegliatin, a potential first-in-class oral glucokinase activator currently in a US Phase 3 trial for type 1 diabetes.
  • Cadisegliatin received Breakthrough Therapy designation from the FDA for its potential role as an adjunctive treatment for type 1 diabetes.
  • The company notes that cadisegliatin's safety & efficacy are unestablished & no guarantee exists for regulatory approval or commercial availability.